drugset / Trial / NCT02888080
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
Timeline
- Start
- 2016-12-19
- Primary completion
- 2019-03-04
- Completion
- 2019-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 300 mg | Subcutaneous |